Brokerages Set Harrow, Inc. (NASDAQ:HROW) Target Price at $61.40

Harrow, Inc. (NASDAQ:HROW - Get Free Report) has received a consensus recommendation of "Buy" from the six analysts that are covering the company, Marketbeat reports. Six analysts have rated the stock with a buy recommendation. The average 1-year target price among analysts that have issued a report on the stock in the last year is $61.40.

A number of equities analysts recently weighed in on the stock. William Blair began coverage on shares of Harrow in a report on Tuesday. They issued an "outperform" rating for the company. HC Wainwright raised their price target on Harrow from $57.00 to $60.00 and gave the stock a "buy" rating in a research note on Monday, May 12th. BTIG Research initiated coverage on Harrow in a research report on Thursday. They set a "buy" rating and a $62.00 price objective for the company. Finally, B. Riley lowered their target price on Harrow from $69.00 to $65.00 and set a "buy" rating on the stock in a report on Tuesday, April 1st.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of HROW. GF Fund Management CO. LTD. purchased a new stake in shares of Harrow in the 4th quarter worth approximately $25,000. Quarry LP bought a new position in Harrow in the first quarter worth approximately $32,000. Tower Research Capital LLC TRC lifted its holdings in Harrow by 769.5% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,652 shares of the company's stock worth $55,000 after buying an additional 1,462 shares during the period. Aquatic Capital Management LLC bought a new stake in Harrow during the 4th quarter valued at $78,000. Finally, AlphaQuest LLC boosted its position in Harrow by 452.8% during the 4th quarter. AlphaQuest LLC now owns 3,527 shares of the company's stock valued at $118,000 after acquiring an additional 2,889 shares in the last quarter. Institutional investors own 72.76% of the company's stock.

Harrow Trading Down 1.4%

Shares of Harrow stock traded down $0.45 during midday trading on Thursday, reaching $31.16. 332,618 shares of the company's stock traded hands, compared to its average volume of 501,650. The stock has a 50 day moving average of $26.00 and a 200-day moving average of $29.77. Harrow has a 12 month low of $16.87 and a 12 month high of $59.23. The company has a market cap of $1.14 billion, a PE ratio of -33.15 and a beta of 0.40. The company has a debt-to-equity ratio of 3.23, a quick ratio of 1.44 and a current ratio of 1.55.

Harrow (NASDAQ:HROW - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.38) EPS for the quarter, missing analysts' consensus estimates of $0.02 by ($0.40). Harrow had a negative net margin of 19.75% and a negative return on equity of 45.57%. The firm had revenue of $47.83 million during the quarter, compared to analysts' expectations of $57.00 million. As a group, equities analysts expect that Harrow will post -0.53 EPS for the current fiscal year.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.